
## **American Urological Association Annual Meeting**

#### **2023 AUA**

April 28-May 1, 2023





The compilation of presentations is for educational purposes only. Copies of presentations obtained through the hyperlinks are live the day of the presentation and per the meeting's guidelines, the hyperlink links to either the Pfizer Conference Publications Portal or the conference website for obtaining the presentation. Copies of presentations obtained through hyperlinks are for personal use only and may not be reproduced without permission from the conference and the author of those presentations. All copyrights protected by law. Solely for non-commercial use.

#### **Pfizer/Alliance-Sponsored Oral Presentation**

#### PD09: Bladder Cancer: Invasive I

Friday, April 28

1:00 PM - 3:00 PM (CST)

**Avelumab** 

Presentation 23-3468

2:30 PM - 2:40 PM (CST)

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy

Valderrama B

Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in US and Canada.

**View Presentation** 

## Pfizer/Alliance-Sponsored Poster Discussions

## MP06: Health Services Research: Quality Improvement & Patient Safety I

Friday, April 28

7:00 AM - 9:00 AM (CST)

Relugolix

Presentation 23-1431

Diabetes, Hypertension, and Hyperlipidemia in Patients with Prostate Cancer May Predict Risk of Cardiovascular Events after Initiating ADT

Sieber P

Presentation is supported by Myovant and Pfizer Alliance.

**View Presentation** 

# MP11: Prostate Cancer: Advanced (including Drug Therapy) I

Friday, April 28

9:30 AM - 11:30 AM (CST)

Relugolix

Presentation 23-2999

Preferences for Key Attributes of Clinically Available Androgen Deprivation Therapies Among Men with Prostate Cancer

Collins S

**View Presentation** 

### **Pfizer/Alliance-Sponsored Oral Presentations**

#### **Plenary: Saturday Morning**

Saturday, April 29

7:45 AM - 11:35 AM (CST)

**Enzalutamide** 

**Presentation 23-9984** 9:45 AM - 10:00 AM (CST)

EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer

Shore N

Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.

**View Presentation** 

#### PD16: Prostate Cancer: Advanced (including Drug Therapy) III

Saturday, April 29

9:30 AM - 11:30 AM (CST)

Relugolix

Presentation 23-1762

10:20 AM - 10:30 AM (CST)

Examining Testosterone Recovery in Androgen Deprivation Therapy for Prostate Cancer Preston M

**View Presentation** 

#### Relugolix

Presentation 23-1425

11:10 AM – 11:20 AM (CST)

Real World Characterization of Patients Receiving Relugolix or Androgen Deprivation Therapy Injections in Combination with Oral Anti-Androgens in 2021 (The REAL ADT ORAL Study): Analysis from a US EMR Database

Hafron J

Presentation is supported by Myovant and Pfizer Alliance.

**View Presentation** 

#### **Enzalutamide**

Presentation 23-4057

11:20 AM - 11:30 AM (CST)

Real-World Outcomes Among Men with Nonmetastatic Castration-sensitive Biochemical Recurrence After Definitive Therapy With Short PSA Doubling Time Receiving Early Secondary Treatment

Freedland S

**View Presentation** 

### Pfizer/Alliance-Sponsored Poster Discussion

#### MP29: Prostate Cancer: Advanced (including Drug Therapy) II

Saturday, April 29

7:00 AM - 9:00 AM (CST)

**Enzalutamide** 

Presentation 23-8225

Treatment Pattern and Health-Related Quality of Life (HRQoL) of Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the United States (US)

Shore N

Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.

**View Presentation**